Atopic Skin Is Associated with a Lack of Phosphatidylcholine–Sphingomyelin Transacylase Activity  by Peiser, Matthias et al.
Chymase participates in chronic dermatitis
by inducing eosinophil infiltration. Lab Invest
82:789–94
Tomimori Y, Muto T, Fukami H, Saito K,
Horikawa C, Tsuruoka N et al. (2002b) Mast
cell chymase regulates dermal mast cell
number in mice. Biochem Biophys Res
Commun 290:1478–82
Tomimori Y, Tsuruoka N, Fukami H, Saito K,
Horikawa C, Saito M et al. (2002c) Role of
mast cell chymase in allergen-induced biphasic
skin reaction. Biochem Pharmacol 64:1187
Tani K, Ogushi F, Kido H, Kawano T, Kunori Y,
Kamimura T et al. (2000) Chymase is a potent
chemoattractant for human monocytes and
neutrophils. J Leukoc Biol 67:585–9
Watanabe N, Tomimori Y, Saito K, Miura K, Wada
A, Tsudzuki M, Fukuda Y (2002) Chymase
inhibitor improves dermatitis in NC/Nga
mice. Int Arch Allergy Immunol 128:229–34
Weidinger S, Rummler L, Klopp N, Wagenpfeil S,
Baurecht HJ, Fischer G et al. (2005) Associa-
tion study of mast cell chymase polymorph-
isms with atopy. Allergy 60:1256–61
Yoshikawa T, Imada T, Nakakubo H,
Nakamura N, Naito K (2001) Rat mast cell
protease-I enhances immunoglobulin
E production by mouse B cells stimulated
with interleukin-4. Immunology 104:
333–40
Atopic Skin Is Associated with a Lack of
Phosphatidylcholine–Sphingomyelin Transacylase Activity
Journal of Investigative Dermatology (2007) 127, 973–975. doi:10.1038/sj.jid.5700623; published online 9 November 2006
TO THE EDITOR
The clinical phenotype of atopic der-
matitis (AD) results from complex inter-
actions of individual susceptibility and
environmental factors, and of the state
of immune responses. An impaired
barrier function of the epidermis is
more and more seen as a predisposing
factor for AD development rather than
as a consequence (Bos et al., 1994;
Jensen et al., 2004; Palmer et al., 2006;
see for a review, Proksch et al., 2003).
An intact stratum corneum assembled
by corneocytes and extracellular lipids
helps to prevent the sensitizing aller-
gens from entering. Heritable defects
giving rise to abnormal cornification
and to alterations in lipid composition
increase the opportunity of immuno-
logically active environmental substances
to contact and to activate antigen-
presenting cells that are required to
provoke the eczematous skin lesions.
The amount of total stratum cor-
neum lipids is consistently decreased in
AD patients, but particularly changes in
content and composition of ceramides
are suspected to facilitate transepider-
mal allergen transfer (see for a review,
Proksch et al., 2003). The actual local
ceramide content is determined by a
network of forming and degrading
activities. Ceramide levels in AD were
found to be reduced by impaired
sphingomyelinase activities (Jensen
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Figure 1. Atopic skin specimens lack PC–SM transacylase activity. Fluorescence-labelled C5-PC was
added to whole epidermal cell homogenates of normal and of AD skin specimens, and reactions
proceeded for 15 minutes. A typical HPTLC plate is shown. State of AD: subacute (1), acute (2, 3), and
chronic (4, 5) (Cer, ceramide; FA, fatty acid; PC, phosphatidylcholine; SM, sphingomyelin). Whole-cell
homogenates of healthy skin specimen and of clinically and histologically diagnosed AD skin biopsies
from affected sites were obtained by treatment with dispase I and trypsin followed by sonication in 50 mM
3-[N-morpholino]propane sulfonic acid (pH 7.4), 1 mM EDTA, 1 protease inhibitor cocktail (Roche,
Mannheim, Germany). Protein concentrations were determined by using a Micro BCA protein assay kit
(Pierce, Rockford, IL). For assays of enzymatic activities, fluorescent lipids at final concentrations of 5mM
were injected into a stirring solution of 50 mM 3-[N-morpholino]propane sulfonic acid (pH 7.4), 5mM fatty-
acid-free bovine albumin (Sigma, Deisenhofen, Germany). For SMase assay, 5 mM MgCl2, for SM deacylase
assay 2.5 mM CaCl2, and for SM synthase 20 mM EDTA was present. Fluorescent BODIPY FL lipids were:
C5-SM, 1,2-bis C11-PC (both of the acyl-chains labelled), C5-HPC (acyl-chain in C2-position labelled),
C5-cer (Molecular Probes, Leiden, The Netherlands). Homogenates were added at final cellular protein
concentrations of 0.2 mg/ml. HPTLC was performed on silica-gel 60 glass plates (Merck, Darmstadt,
Germany). Mobile phase: chloroform:methanol:H2O¼55:20:3 (v:v:v). Standards were commercially
available BODIPY FL lipids as well as lipids prepared thereof (Molecular Probes; Wanner et al., 2004).
Abbreviation: AD, atopic dermatitis; PC, phosphatidylcholine; SM, sphingomyelin
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et al., 2004) and by increased activity of
a glucosylceramide/sphingomyelin
(SM) deacylase, releasing free fatty
acids (Murata et al., 1996; Hara et al.,
2000; Higuchi et al., 2000). In addition,
the biosynthesis of free glucosylcer-
amides and of free ceramides was
found to be decreased in affected AD
skin areas (Macheleidt et al., 2002).
In normal keratinocytes, we have
found a novel phosphatidylcholine
(PC)–SM transacylase (Wanner et al.,
2004) (Figure 1). Such a fatty acid
transfer from PC to SM was confirmed
in L929 cells (Meyer et al., 2005). These
activities might be involved in tuning
up the fatty acid profile of SM for later
use in stratum corneum ceramides. We
have therefore compared the PC–SM
transacylase activities in keratinocytes
isolated from normal and from atopic
skin (in adherence to the Declaration of
Helsinki Principles received as residual
material after plastical mamma-surgery
and as otherwise discarded diagnostic
material with the approval of the local
ethics commission).
None of the 10 AD specimens tested
revealed any detectable PC–SM transa-
cylase activity. Regardless of the
dermatitis state, a transfer of fluores-
cence-labelled fatty acids from C5-PC to
SM could not be found (Figure 1;
Table 1). In normal skin, the yield of
labelled SM product was low (Figure 1),
but was detectable in four of five
samples under standard assay conditions
(Table 1). For both the negative normal
skin and the AD skin samples, prolonged
incubation times and higher substrate
and homogenate concentrations did not
yield amounts of C5-SM product passing
over the detection limit (not shown).
When 1,2-bis C11-PC containing more
physiologic fatty acids was used as the
substrate, a fatty acid transfer could be
detected in samples of normal skin but
not in AD samples (not shown).
The amounts of C5-SM product
formed in vitro by normal skin samples
are low. In vivo, however, SM is
embedded in a network of metabolizing
enzyme activities. A continuous hydro-
lysis of SM molecules containing new
acyl-chains would allow a steady flux
of acyl-chains from PC to SM.
In contrast to the results of Jensen et al.
(2004), all of the AD samples revealed a
Table 1. Semiquantitative determination of nSMase and of PC–SM
transacylase activities in normal and in AD skin specimen
Probe nSMase PC–SM transacylase
Normal #1 4.270.8 0.3270.15
Normal #2 3.870.6 0.2270.13
Normal #3 4.070.6 0.2870.07
normal #4 3.770.8 ND
normal #5 3.771.2 0.3070.09
AD#1 4.070.5 ND
AD #2 3.570.8 ND
AD #4 3.870.8 ND
AD #5 2.971.2 ND
AD #6 3.270.9 ND
AD #7 3.970.4 ND
AD #8 3.570.8 ND
AD #9 4.170.5 ND
AD #10 4.570.7 ND
AD, atopic dermatitis; ND, not detectable; nSMase, neutral sphingomyelinase; PC–SM, phosphati-
dylcholine–sphingomyelin.
Specific activities in nmol/mg [protein]min (initial velocities; mean of three measurements7SD).
Assay conditions were as described in Figure 1. The intensities of fluorescent bands of products and of
standards (BODIPY FL C5-cer for nSMase; BODIPY FL C5-SM for transacylase; calculation of amounts
according to quantities indicated by Molecular Probes) on HPLTC plates were densitometrically
analyzed using a gel doc 2000 station equipped with a Transilluminator 2000 light source (302 nm
lamp plus UV filter) and Quantity One 4.2.1 software (Biorad, Mu¨nchen, Germany).
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Figure 2. Lipid metabolism in AD sample no. 4. Fluorescence-labelled C5-SM with 5 mM MgCl2,
C5-ceramide with 20 mM EDTA, and 1,2-bis C11-PC were added to whole-cell homogenates of chronic
AD sample no. 4, and reactions proceeded for 15 minutes. A typical HPTLC plate is shown.
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normal neutral sphingomyelinase activity
(Table 1). SM deacylase activity could
not be observed (not shown).
AD sample no. 4 emerged as a special
specimen. We never found free fatty
acids to be generated from PC in other
skin samples, but surprisingly, chronic
dermatitis sample no. 4 hydrolyzed C5-
PC (Figure 1). When 1,2-bis C11-PC in
which both of the esterified fatty acids are
labelled was used as the substrate, C11-
free fatty acid was detected (Figure 2). In
contrast to all of the other AD specimens,
sample no. 4 generated some products
detectable between the plate origin and
1,2-bis C11-PC. These bands might corre-
spond to C11-SM or to lyso-PC. The faint
band intensities, however, point to rather
low amounts as products of 1,2-bis C11-
PC containing only one labelled fatty
acid reveal increased emission intensities
as compared to 1,2-bis C11-PC in which
the adjacent fluorophores quench them-
selves. The more intense emission of the
free fatty acid might indicate that both of
the acyl-chains were hydrolyzed but
mostly not re-esterified (Figure 2).
Missing transacylase in a normal
skin specimen indicates that the loss
of this enzymatic activity is not suffi-
cient for AD development. On the other
hand, one of the AD samples (no. 4)
might contain some transacylase activ-
ity that does not protect against AD.
Conversely interpreted, the one excep-
tional normal individual might be at
risk for AD development, and the
special AD patient might await remis-
sion of disease.
In conclusion, we found that AD
skin may be associated with a lack of
PC-SM transacylase activity.
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TO THE EDITOR
Skin cancer results from chronic solar
exposure, especially in fair-skinned
people (Armstrong et al., 1997). The
International Agency for Research on
Cancer (IARC) assessed the role of
sunscreens in skin cancer prevention
and concluded that ‘‘There is limited
evidence in humans for a cancer pre-
ventive effect of the topical use of
sunscreen formulations against squa-
mous-cell carcinoma of the skin’’
(IARC, 2001). Furthermore, there was
‘‘inadequate evidence’’ for any preven-
tive effects against basal cell carcinoma
and malignant melanoma.
Photocarcinogenesis involves DNA
photodamage, inadequate DNA repair,
probable failure of apoptosis, mutation
(Wikonkal and Brash, 1999), clonal
expansion of mutated cells (Brash
et al., 2005), and UVR-induced immuno-
suppression (Ullrich, 2002; Ullrich
et al., 2002). Most human photobiology
research is with a single erythemal
exposure that is not representative of
the effects of repeated sub-erythemal
exposure, which may initiate adaptive
responses such as tanning and DNA
repair (Sheehan et al., 1998, 2002; Agar
Abbreviations: CPD, cyclobutane pyrimidine dimer; LC, Langerhans cell; MED, minimal erythema dose;
SBC, sunburn cell; SSR, solar simulating radiation; TT, thymine dimer
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